Subtype
Breast Adenocarcinoma
CI-CAN-00002035Explore in graph →
686 active trials9 approved drugs104 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002035Explore in graph →
Clinical trials
1,713 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (278)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02984683 | Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer | terminated | Phase 2 | 23 | SanofiINDUSTRY | 5 | Sep 8, 2021 | clinicaltrials |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | terminated | Phase 1 | 2 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 31, 2021 | clinicaltrials |
| A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer |
| terminated |
| Phase 2 |
| 6 |
| University of Wisconsin, MadisonOTHER |
| 1 |
| Aug 18, 2021 |
| clinicaltrials |
| NCT01755130 | Laser Optoacoustic and Ultrasonic Imaging System Assembly in Finding Changes in Tumors in Patients With Breast Cancer | terminated | N/A | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2021 | clinicaltrials |
| NCT03244358 | Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer | terminated | Phase 2 | 12 | Sun Yat-sen UniversityOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT03055312 | Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer(SYSUCC-007) | terminated | Phase 3 | 36 | Sun Yat-sen UniversityOTHER | 1 | Jan 28, 2021 | clinicaltrials |
| NCT02698176 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) | terminated | Phase 1 | 13 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 27, 2021 | clinicaltrials |
| NCT02993094 | Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 31 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT02368691 | Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC) | terminated | Phase 2 | 32 | GTxINDUSTRY | 1 | Nov 18, 2020 | clinicaltrials |
| NCT03292172 | A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer | terminated | Phase 1 | 36 | Hoffmann-La RocheINDUSTRY | 5 | Nov 6, 2020 | clinicaltrials |
| NCT01745367 | Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer(BATON-BC) | terminated | Phase 2 | 30 | AVEO Pharmaceuticals, Inc.INDUSTRY | 10 | Oct 27, 2020 | clinicaltrials |
| NCT02095210 | HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025 | terminated | Phase 1 | 2 | Dorte NielsenOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT01697293 | PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer | terminated | Phase 1 / Phase 2 | 34 | Prescient Therapeutics, Ltd.INDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT02892734 | Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer | terminated | Phase 2 | 3 | Northwestern UniversityOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | terminated | Phase 1 | 60 | Eli Lilly and CompanyINDUSTRY | 6 | Jun 9, 2020 | clinicaltrials |
| NCT01409811 | Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid | terminated | N/A | 9 | City of Hope Medical CenterOTHER | 1 | May 8, 2020 | clinicaltrials |
| NCT01060345 | A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ | terminated | Phase 2 | 20 | University of ChicagoOTHER | 1 | Apr 9, 2020 | clinicaltrials |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) | terminated | Phase 1 | 21 | Tocagen Inc.INDUSTRY | 1 | Feb 7, 2020 | clinicaltrials |
| NCT02003092 | RX-5902 Treatment of Subjects With Triple Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 18 | Rexahn Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 6, 2020 | clinicaltrials |
| NCT01891357 | Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer | terminated | Phase 2 | 64 | Women's Cancer Study Group GmbHOTHER | 1 | Sep 17, 2019 | clinicaltrials |
| NCT03318562 | A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC | terminated | Phase 2 | 3 | Effector TherapeuticsINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT01138553 | Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer | terminated | Early Phase 1 | 4 | University of California, San DiegoOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT02078752 | A Study Of PF-06647263 In Patients With Advanced Solid Tumors | terminated | Phase 1 | 60 | PfizerINDUSTRY | 1 | Apr 29, 2019 | clinicaltrials |
| NCT02299635 | A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations | terminated | Phase 2 | 19 | PfizerINDUSTRY | 6 | Jan 8, 2019 | clinicaltrials |
| NCT01912963 | Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer | terminated | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 5, 2018 | clinicaltrials |
| NCT03358004 | the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment(VICTOR3) | terminated | Phase 2 | 4 | Mario Negri Institute for Pharmacological ResearchOTHER | 3 | Oct 5, 2018 | clinicaltrials |
| NCT02023008 | Interactive Gentle Yoga in Improving Quality of Life in Patients With Stage I-III Breast Cancer Undergoing Radiation Therapy | terminated | N/A | 6 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | terminated | Phase 1 | 18 | Celldex TherapeuticsINDUSTRY | 1 | Apr 30, 2018 | clinicaltrials |
| NCT02379585 | Fasting on Newly Diagnosed Breast Cancer(STEFNE) | terminated | Phase 1 / Phase 2 | 8 | Western Regional Medical CenterOTHER | 1 | Apr 24, 2018 | clinicaltrials |
| NCT02365714 | CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)(CK-SAPBI) | terminated | Phase 1 / Phase 2 | 2 | Georgetown UniversityOTHER | 1 | Apr 13, 2018 | clinicaltrials |
| NCT02345772 | Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy(Neohttp) | terminated | Phase 1 / Phase 2 | 4 | Western Regional Medical CenterOTHER | 1 | Feb 20, 2018 | clinicaltrials |
| NCT01372618 | Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor | terminated | Phase 1 / Phase 2 | 9 | NYU Langone HealthOTHER | 1 | Dec 27, 2017 | clinicaltrials |
| NCT01319539 | MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer | terminated | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Aug 30, 2017 | clinicaltrials |
| NCT01754519 | Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery | terminated | Phase 2 | 1 | Roswell Park Cancer InstituteOTHER | 1 | Jul 7, 2017 | clinicaltrials |
| NCT01918306 | GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 11 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 27, 2017 | clinicaltrials |
| NCT01151449 | Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Apr 11, 2017 | clinicaltrials |
| NCT01729884 | Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer | terminated | Phase 2 | 3 | University of WashingtonOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT02213744 | MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients(HERMIONE) | terminated | Phase 2 / Phase 3 | 113 | Merrimack PharmaceuticalsINDUSTRY | 9 | Jan 6, 2017 | clinicaltrials |
| NCT01875198 | Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer | terminated | N/A | 1 | Yonsei UniversityOTHER | 1 | Nov 22, 2016 | clinicaltrials |
| NCT01391039 | Diagnostic Study of Early Breast Cancer Using Ultrasound | terminated | N/A | 12 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 30, 2015 | clinicaltrials |
| NCT01238133 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer | terminated | Phase 1 | 14 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2015 | clinicaltrials |
| NCT00857714 | Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast | terminated | N/A | 1 | Indiana UniversityOTHER | 1 | Jul 8, 2015 | clinicaltrials |
| NCT01071564 | RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery | terminated | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00079326 | Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer | terminated | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2014 | clinicaltrials |
| NCT01329640 | Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01) | terminated | Phase 2 | 9 | Instituto do Cancer do Estado de São PauloOTHER | 1 | May 21, 2014 | clinicaltrials |
| NCT01705340 | Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery | terminated | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00039455 | Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer | terminated | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00016276 | Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer | terminated | Phase 3 | 396 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00817362 | Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer | terminated | Phase 2 | 29 | Infinity Pharmaceuticals, Inc.INDUSTRY | 2 | Dec 11, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Sep 8, 2021source: clinicaltrials